Luigi Lorini/LinkedIn
Apr 27, 2025, 16:13
Luigi Lorini: Sharing my thoughts on crucial topics about HNSCC during the latest ESMO meeting in Barcelona
Luigi Lorini, Medical Oncologist at Humanitas Research Hospital, shared a post on LinkedIn:
“What’s next for immunotherapy in head and neck cancer? Is PD-L1 CPS evaluation on the primary tumor as reliable as on recurrent/metastatic lesions? Some insights from the CONCORDL-1 study. What are the preliminary insights from the PRIME trial (combining ICI + PARPi as neoadjuvant-adjuvant strategy in locally advanced HNSCC)?
I had the opportunity to share my thoughts on these crucial topics during the latest ESMO meeting in Barcelona.
A big thank you to Video Journal of Oncology (VJOncology) for the invitation and the valuable support!Stay tuned for more updates – the field is evolving fast!
Web link.”
You Can Read Insights from CONCORDL-1 study
More posts featuring Luigi Lorini.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 27, 2025, 16:50
Apr 27, 2025, 16:49
Apr 27, 2025, 16:29
Apr 27, 2025, 16:28
Apr 27, 2025, 16:07